Methylation Profiling Kit for Substance Use Disorder Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing substance use disorders, such as nicotine, alcohol, and cannabis dependence, rely on clinical observations rather than reliable laboratory tests, lacking objective indicators and effective diagnostic tools.
Innovation Solution
A screening kit utilizing solid substrates with probes specific to the methylation status of CpG dinucleotide repeat motifs in peripheral blood cells, associated with substance use disorders, to determine predisposition or likelihood of substance use disorders through nucleic acid methylation profiling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clinical observation methods are used for diagnosing substance use disorders, then the diagnostic process is simple and does not require complex laboratory equipment, but the diagnosis lacks objectivity and reliability
Solution Approach 1:
The patent replaces subjective clinical observation (mechanical/physical examination) with molecular biological detection methods. Specifically, it uses methylation-specific PCR and other molecular techniques to detect methylation status of specific genes (such as DRD2, OPRM1) in blood samples, substituting the mechanical clinical diagnosis process with objective molecular-level detection that provides reliable diagnostic data for substance use disorders
Solution Approach 2:
The patent introduces methylation status of specific genes as an intermediary biomarker between substance use behavior and clinical diagnosis. By detecting methylation patterns (epigenetic modifications) in genes related to substance reward pathways, the patent creates an objective intermediate indicator that bridges the gap between subjective clinical symptoms and reliable laboratory-based diagnosis
2Measurement precision
If no reliable laboratory test is developed, then clinical diagnosis can be performed without specialized testing resources, but objective indicators for diagnosis are lacking
Solution Approach 1:
The patent changes the detection parameter from macroscopic clinical symptoms to microscopic molecular markers. It specifically detects methylation status (methylated vs. unmethylated states) of CpG sites in promoter regions of substance-related genes, transforming the diagnostic parameter to a molecular level that provides precise measurement of substance use disorder risk and status
Solution Approach 2:
The patent segments the complex diagnostic process into specific detectable molecular components. It identifies and detects methylation status of individual genes (DRD2, OPRM1, etc.) and specific CpG sites within these genes, breaking down the overall diagnostic challenge into discrete, measurable molecular units that can be detected with precision using PCR and other molecular techniques
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides an objective and reliable method for diagnosing substance use disorders by identifying specific methylation patterns in blood cells, enabling accurate classification and potential treatment evaluation.
Implementation Method 1
at least one probe specific for methylation status of a CpG dinucleotide repeat motif expressed by a peripheral blood cell or its derivative
Data Source
AI summary
The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.